Alterity Therapeutics Price To Book vs. Shares Owned By Institutions

ATHE Stock  USD 1.09  0.03  2.83%   
Based on Alterity Therapeutics' profitability indicators, Alterity Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in December. Profitability indicators assess Alterity Therapeutics' ability to earn profits and add value for shareholders. As of November 30, 2024, Price To Sales Ratio is expected to decline to 4.31. In addition to that, Days Sales Outstanding is expected to decline to 348.68. At present, Alterity Therapeutics' Total Other Income Expense Net is projected to increase significantly based on the last few years of reporting. The current year's Interest Income is expected to grow to about 514.6 K, whereas Net Loss is projected to grow to (18.2 M).
For Alterity Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Alterity Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Alterity Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Alterity Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Alterity Therapeutics over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
For information on how to trade Alterity Stock refer to our How to Trade Alterity Stock guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alterity Therapeutics. If investors know Alterity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alterity Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.91)
Revenue Per Share
0.6
Quarterly Revenue Growth
0.384
Return On Assets
(0.53)
Return On Equity
(1.04)
The market value of Alterity Therapeutics is measured differently than its book value, which is the value of Alterity that is recorded on the company's balance sheet. Investors also form their own opinion of Alterity Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Alterity Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alterity Therapeutics' market value can be influenced by many factors that don't directly affect Alterity Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alterity Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alterity Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alterity Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Alterity Therapeutics Shares Owned By Institutions vs. Price To Book Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Alterity Therapeutics's current stock value. Our valuation model uses many indicators to compare Alterity Therapeutics value to that of its competitors to determine the firm's financial worth.
Alterity Therapeutics is rated fifth in price to book category among its peers. It is rated below average in shares owned by institutions category among its peers producing about  1.20  of Shares Owned By Institutions per Price To Book. Comparative valuation analysis is a catch-all technique that is used if you cannot value Alterity Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Alterity Shares Owned By Institutions vs. Price To Book

Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.

Alterity Therapeutics

P/B

 = 

MV Per Share

BV Per Share

 = 
1.07 X
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.

Alterity Therapeutics

Shares Held by Institutions

 = 

Funds and Banks

+

Firms

 = 
1.28 %
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.

Alterity Shares Owned By Institutions Comparison

Alterity Therapeutics is currently under evaluation in shares owned by institutions category among its peers.

Alterity Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Alterity Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Alterity Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Alterity Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Alterity Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income4.8 MM
Operating Income-19.6 M-18.6 M
Net Loss-19.1 M-18.2 M
Income Tax Expense46.1 K43.8 K
Income Before Tax-19.1 M-18.1 M
Total Other Income Expense Net524.3 K550.5 K
Interest Income268.4 K514.6 K
Net Loss-19.1 M-18.2 M
Net Loss-12.4 M-13 M
Net Interest Income268.4 K281.8 K
Change To Netincome68 K71.4 K
Net Loss(0.01)(0.01)
Income Quality 0.66  0.75 
Net Income Per E B T 1.00  0.79 

Alterity Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Alterity Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Alterity Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Alterity Therapeutics' important profitability drivers and their relationship over time.

Use Alterity Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alterity Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alterity Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Alterity Therapeutics Pair Trading

Alterity Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to Alterity Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alterity Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alterity Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alterity Therapeutics to buy it.
The correlation of Alterity Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alterity Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alterity Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Alterity Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Alterity Therapeutics position

In addition to having Alterity Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Aggressive Defence Thematic Idea Now

Aggressive Defence
Aggressive Defence Theme
Macroaxis small cap, aggressive-outlook picks designed for investors that are willing to accept higher levels of risk to hedge exposure to above-average market volatility. The Aggressive Defence theme has 50 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Aggressive Defence Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Alterity Therapeutics is a strong investment it is important to analyze Alterity Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Alterity Therapeutics' future performance. For an informed investment choice regarding Alterity Stock, refer to the following important reports:
Check out Trending Equities.
For information on how to trade Alterity Stock refer to our How to Trade Alterity Stock guide.
You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
To fully project Alterity Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Alterity Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Alterity Therapeutics' income statement, its balance sheet, and the statement of cash flows.
Potential Alterity Therapeutics investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Alterity Therapeutics investors may work on each financial statement separately, they are all related. The changes in Alterity Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Alterity Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.